RxDoctor Payments Data

Bonnie Earley

Acute Care · Meridian, MSNPI 1912981085

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 115 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 18 manufacturers reported payments, led by Merck at 24.1% of the total.

$2,470in general payments, 2019–2025

Across 115 payments — averaging $21.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$594
  • Johnson & Johnson$395
  • Abbott$275
  • E.r. Squibb & Sons, L.L.C.$212
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$188
  • AstraZeneca$169
  • plus $636 from 12 others

What the payments were for

  • Food & beverage$2,470100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,470 in reported general payments places this provider in the 80th percentile of 223 acute care providers in Mississippi.

See all acute care providers in Mississippi

Medicare billing

Part B allowed, 2024
$31,295
Medicare patients
182
Services billed
331

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban23$12,746
Rosuvastatin Calcium35$250
ClopidogrelClopidogrel Bisulfate33$235
Atorvastatin Calcium17$132
Nitroglycerin17$117
Diltiazem 24hr Er (Cd)Diltiazem Hcl12$87
Isosorbide Mononitrate ErIsosorbide Mononitrate18$83
Losartan Potassium16$72
Metoprolol Tartrate24$58
Carvedilol20$55
Furosemide23$52
Amlodipine Besylate14$41

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$68$12,74623 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 223 acute care providers in Mississippi.

Other acute care in Meridian

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →